摘要
目的探讨曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭患者的临床效果。方法分析辽宁省盘锦市中心医院2013年1月~2016年4月收治的60例冠心病心力衰竭患者的临床资料,采用随机数字表法进行分组,对照组(地高辛治疗组)30例和观察组(曲美他嗪联合琥珀酸美托洛尔治疗组)30例。观察两组患者治疗前后生命体征及心功能变化情况、临床疗效。结果两组患者治疗前收缩压(SBP)、舒张压(DBP)、心率(HR)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、左室射血分数(LVEF)、B型尿钠肽(BNP)比较,差异无统计学意义(P>0.05)。两组治疗后SBP、DBP、BNP均低于治疗前,HR慢于治疗前,LVEDD、LVESD小于治疗前,LVEF高于治疗前,差异有统计学意义(P<0.05)。观察组治疗后SBP、DBP、BNP均低于对照组,HR慢于对照组,LVEDD、LVESD小于对照组,LVEF高于对照组,差异有统计学意义(P<0.05)。观察组总有效率高于对照组,差异有统计学意义(P<0.05)。结论曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭患者的临床症状改善明显,效果良好,值得临床推广应用。
Objective To explore clinical effect of Trimetazidine combined with Metoprolol Succinate in the treatment of patients with coronary disease and heart failure. Methods Clinical data of 60 patients with coronary disease and heart failure in Central Hospital of Panjin City, Liaoning Province from January 2013 to April 2016 were analyzed. All patients were divided into two groups by random number table method, control group (digoxin therapy group) was 30 cases and observation group (Trimetazidine combined with Metoprelol Suecinate therapy group) was 30 cases. The vital signs changing, heart function changing before and after treatment, clinical effect between two groups were observed. Results SBP, DBP, HR, LVEDD, LVESD, LVEF, BNP of two groups before treatment were compared, with no statisti- cal difference (P 〉 0.05). SBP, DBP, BNP of two groups after treatment were lower than before treatment, HR of two groups after treatment was slower than before treatment, LVEDD, LVESD of two groups after geatment were less than before treatment, LVEF of two groups after treatment was higher than before treatment, the differences were statistically significant (P 〈 0.05). SBP, DBP, BNP of observation group after treatment were lower than those of control group, HR of observation group after treatment was slower than that of control group, LVEDD, LVESD of observation group after treatment were less than those of control group, LVEF observation group after treatment was higher than that of control group, the differences were statistically significant (P 〈 0.05). Total effective rate of observation group was higher than that of control group, the difference was statistically significant (P 〈 0.05). Conclusion Clinical symptom of Trimetazi- dine combined with Metoprolol Succinate in the treatment of patients with coronary disease and heart failure can im- prove obviously, the effect is good, it is worthy of clinical popularization and application.
出处
《中国医药导报》
CAS
2017年第2期131-134,共4页
China Medical Herald
关键词
曲美他嗪
琥珀酸美托洛尔
冠心病
心力衰竭
Trimetazidine
Metoprolol Succinate
Coronary disease
Heart failure